The $69.9M cash runway through 2027 removes near-term financing overhang for a clinical-stage biotech. BASECAMP enrollment completion in Q3 2026 is the next major catalyst — any interim data readout before then could drive significant volatility. The widening net loss is expected for a company advancing Phase 2 trials and is not a concern given the strong cash position. Monitor for additional clinical site activations and any early efficacy signals from TRAILHEAD.
Price Chart
Executive Summary
Satellos Bioscience reported Q1 2026 financial results showing a net loss of $9.8M ($0.53 per share), widening from $6.1M ($0.44 per share) in Q1 2025, driven by increased R&D spending on the BASECAMP and TRAILHEAD Phase 2 trials. The company raised $57.2M gross ($51.9M net) in a February 2026 equity offering, ending the quarter with $69.9M in cash and short-term investments, providing runway through 2027. Key clinical milestones include BASECAMP enrollment on track for Q3 2026 completion and TRAILHEAD initiated in the U.S.
Key Facts
- Net loss of $9.8M for Q1 2026 vs $6.1M in Q1 2025
- Cash and short-term investments of $69.9M as of March 31, 2026, up from $27.7M at Dec 31, 2025
- February 2026 equity offering raised $57.2M gross ($51.9M net) from 5,168,019 shares at $10.10/share and 495,049 pre-funded warrants
- BASECAMP Phase 2 pediatric DMD study actively enrolling at 11 sites; enrollment completion on track for Q3 2026
- TRAILHEAD Phase 2 adult DMD study initiated in the U.S. after FDA review period
- R&D expenses increased 61% to $7.3M from $4.5M, driven by clinical trial costs
- G&A expenses increased 41% to $2.7M from $1.9M, due to Nasdaq listing costs and higher headcount
- Accumulated deficit reached $91.7M as of March 31, 2026
- Share consolidation completed on January 27, 2026 (12:1 reverse split)
- Company has no revenue and expects continued losses as R&D programs advance
Financial Impact
Net loss widened by $3.6M YoY to $9.8M; cash position strengthened by $42.2M to $69.9M after $51.9M net equity raise
Risk Factors
- Clinical trial failure or disappointing data from BASECAMP or TRAILHEAD
- Need for additional dilutive financing beyond 2027 if trials extend or expand
- Execution risk in enrolling BASECAMP on schedule across multiple geographies
- Regulatory delays or FDA clinical holds on ongoing studies
- Foreign exchange exposure from Canadian dollar-denominated expenses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003453 |
| Exhibit: exh_992.htm | 0001171843-26-003453 |
| Exhibit: exh_993.htm | 0001171843-26-003453 |
| Exhibit: exh_995.htm | 0001171843-26-003453 |
| Exhibit: exh_994.htm | 0001171843-26-003453 |
| Document: f6k_051526.htm | 0001171843-26-003453 |
| Document: 0001171843-26-003453-index-headers.html | 0001171843-26-003453 |
| Document: 0001171843-26-003453-index.html | 0001171843-26-003453 |
| Document: 0001171843-26-003453.txt | 0001171843-26-003453 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.88 (+7.17%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.88 (+2.69%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.88 (−14.53%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.88 (−26.50%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.88 (−31.34%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.88 (−24.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers